Detalles de la búsqueda
1.
A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada.
BMC Anesthesiol
; 16(1): 114, 2016 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27852231
2.
EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.
Health Qual Life Outcomes
; 10: 65, 2012 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22691697
3.
Costs associated with outpatient, emergency room and inpatient care for migraine in the USA.
Cephalalgia
; 31(15): 1570-5, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22013140
4.
EuroQol (EQ-5D) health utility scores for patients with migraine.
Qual Life Res
; 20(4): 601-8, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21063786
5.
Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.
J Med Econ
; 24(1): 792-805, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34098842
6.
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population.
J Low Genit Tract Dis
; 14(1): 29-36, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20040833
7.
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Pharmacoecon Open
; 4(2): 235-247, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31531842
8.
Age-based programs for vaccination against HPV.
Value Health
; 12(5): 697-707, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19490561
9.
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.
BMC Infect Dis
; 9: 119, 2009 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-19640281
10.
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
Pharmacoeconomics
; 27(9): 781-92, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19757871
11.
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.
Immunotherapy
; 11(17): 1463-1478, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31738117
12.
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Curr Med Res Opin
; 35(7): 1241-1256, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30649973
13.
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.
Cancer Epidemiol Biomarkers Prev
; 17(7): 1611-22, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18628412
14.
Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Gynecol Oncol
; 111(2): 188-96, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18757080
15.
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Am J Obstet Gynecol
; 198(3): 261.e1-11, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18313445
16.
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Value Health
; 11(7): 1022-32, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18489503
17.
A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.
Pharmacoeconomics
; 26(11): 925-35, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18850762
18.
A multi-type HPV transmission model.
Bull Math Biol
; 70(8): 2126-76, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18841421
19.
Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.
Rheumatol Ther
; 5(1): 57-73, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29633197
20.
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
J Med Econ
; 21(12): 1191-1205, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30188231